Pivotal trial outcomes data for US Food and Drug Administration-approved immunotherapies for small-cell lung cancer
| Trial | Interventions | Results | |||
| ORR | Median DOR | OS | Median PFS | ||
| First-line setting | |||||
| IMpower133 (NCT02763579)179 | Atezolizumab + carboplatin + etoposide | 60.2% (95% CI 53.1% to 67.0%) | 4.2 months | Median OS: 12.3 months (95% CI 10.8 to 15.9) (HR vs chemotherapy 0.70; 95% CI 0.54 to 0.91; p=0.007) | 5.2 months (95% CI 4.4 to 5.6) (HR vs chemotherapy 0.77; 95% CI 0.62 to 0.96; p =0.02) |
| Placebo + carboplatin + etoposide | 64.4% (95% CI 57.3% to 71.0%) | 3.9 months | Median OS: 10.3 months (95% CI 9.3 to 11.3) | 4.3 months (95% CI 4.2 to 4.5) | |
| CASPIAN (NCT03043872)89 | Durvalumab + (carboplatin or cisplatin + etoposide) | 68% (OR vs chemotherapy 1.56; 95% CI 1.10 to 2.22) | 5.1 months | Median OS: 13.0 months (95% CI 11.5 to 14.8) (HR vs chemotherapy 0.73; 95% CI 0.59 to 0.91; p=0.0047) | 5.1 months (95% CI 4.7 to 6.2) (HR vs chemotherapy 0.78; 95% CI 0.65 to 0.94) |
| Carboplatin or cisplatin + etoposide | 58% | 5.1 months | Median OS: 10.3 months (95% CI 9.3 to 11.2) | 5.4 months (95% CI 4.8 to 6.2) | |
DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.